Life Science Investing Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
Life Science Investing Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
Life Science Investing Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Life Science Investing Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Life Science Investing Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
Life Science Investing Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment
Life Science Investing Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference
Life Science Investing Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
